Last reviewed · How we verify
Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)
This study is being conducted to evaluate the safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine (V114) compared to Prevnar™ in healthy adults and toddlers.
Details
| Lead sponsor | Merck Sharp & Dohme LLC |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 150 |
| Start date | Fri Sep 25 2009 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Jan 05 2011 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Pneumococcal Infections
Interventions
- Prevnar™
- V114, Aluminum Adjuvanted
- V114, Aluminum Nonadjuvanted